Only 10% of Clinical Trials are Completed On Time
Medical and operations processes are unreliable, take too long, and can no longer keep up.
CRO Oversight & Collaboration
Over 70% of sponsors outsource site operations and data management. As a result, 73% of ClinOps leaders consider the sponsor-CRO relationship very important. Yet only 30% consider their current relationship management efforts successful.
Clinical teams need ClinOps Insights to aggregate data from disparate sources and facilitate collaborative issue management across internal and external teams.
Real-time best practice KPIs, next generation analytics,
forecasting, alerting, and collaboration capabilities
across all of your CROs and eClinical Systems
Portfolio Monitoring & Continuous Quality
In a recent survey, the vast majority of ClinOps leaders describe their enrollment, patient compliance and site productivity processes as manual, after-the-fact and reactive. It is therefore no surprise that only 30% report they are “successful” in these areas. The result? Over 80% regularly miss milestones, which leads to trial delays and cost overruns.
ClinOps leaders need ClinOps Insights to manage these key processes for their portfolio of studies.
Most clinical teams agree on the value of centralized and risk monitoring, but also find it challenging to automate key performance metrics quickly, affordably, and with flexibility to evolve with changing requirements.
Without a cost effective option, the vast majority of trials proceed without a risk management strategy. ClinOps leaders need Centralized Monitoring to mitigate operational and regulatory risk across their portfolio of studies.
Medical Monitors are under pressure to ensure data quality and safe clinical trials, yet slow patient investigation processes are causing delays in critical decisions, which increases the risk and uncertainty to patients and studies.
Clinical teams need Medical Insights to quickly investigate medical efficacy and patient safety.
“If I wanted to know how many protocol deviations have occurred, I can look at that across the portfolio or by individual study. This has the potential to drive change, as we can get out to sites and reeducate personnel. It also allows us to focus on a particular area of the study.”
- VP of Clinical Operations
Click here to read the full article